These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11819752)

  • 1. Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
    Liu B; Staren E; Iwamura T; Appert H; Howard J
    World J Gastroenterol; 2001 Feb; 7(1):143-8. PubMed ID: 11819752
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
    Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
    J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
    Liu B; Staren E; Iwamura T; Appert H; Howard J
    World J Gastroenterol; 2001 Dec; 7(6):855-9. PubMed ID: 11854916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
    Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
    Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemistry and chemical biology of taxane anticancer agents.
    Miller ML; Ojima I
    Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
    Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
    Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
    Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
    Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
    Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
    Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and cytotoxicity of 2alpha-amido docetaxel analogues.
    Fang WS; Liu Y; Liu HY; Xu SF; Wang L; Fang QC
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1543-6. PubMed ID: 12031338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance reversal activity of taxoids from Taxus cuspidata in KB-C2 and 2780AD cells.
    Kobayashi J; Shigemori H; Hosoyama H; Chen Z; Akiyama S; Naito M; Tsuruo T
    Jpn J Cancer Res; 2000 Jun; 91(6):638-42. PubMed ID: 10874217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
    Untch M; Untch A; Sevin BU; Angioli R; Perras JP; Koechli O; Averette HE
    Anticancer Drugs; 1994 Feb; 5(1):24-30. PubMed ID: 7910494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective drug resistant human osteosarcoma cell lines.
    Burns BS; Edin ML; Lester GE; Tuttle HG; Wall ME; Wani MC; Bos GD
    Clin Orthop Relat Res; 2001 Feb; (383):259-67. PubMed ID: 11210963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
    Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
    Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
    Britten RA; Klein K
    Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of taxol and Taxotere on two different human carcinoma cell lines.
    Garcia P; Braguer D; Carles G; el Khyari S; Barra Y; de Ines C; Barasoain I; Briand C
    Cancer Chemother Pharmacol; 1994; 34(4):335-43. PubMed ID: 7913421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-synthesis of an O-glycosylated docetaxel analogue.
    Nikolakakis A; Haidara K; Sauriol F; Mamer O; Zamir LO
    Bioorg Med Chem; 2003 Apr; 11(7):1551-6. PubMed ID: 12628678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxane sensitivity of ovarian carcinoma in vitro.
    Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
    Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types.
    Reinecke P; Schmitz M; Schneider EM; Gabbert HE; Gerharz CD
    Cancer Invest; 2000; 18(7):614-25. PubMed ID: 11036469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients.
    D'Incalci M
    Ann Oncol; 1997 Dec; 8(12):1183-4. PubMed ID: 9496382
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
    Braakhuis BJ; Hill BT; Dietel M; Kelland LR; Aapro MS; Zoli W; Lelieveld P
    Anticancer Res; 1994; 14(1A):205-8. PubMed ID: 7909419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.